Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C

Issuer: Xtrackers

Asset Class: Equity

TER: 35bps

Trading Currency: GBP

Pays Income: False

Listing Date: 20 Jul 2022

Ticker: XGES

ISIN: IE000KD0BZ68

This fund offers targeted exposure to the rapidly advancing field of genomic healthcare, a sector poised to revolutionize medicine. It invests in global companies that are at the forefront of genetic research and application, including areas like gene sequencing, gene editing (such as CRISPR technology), gene therapy, and molecular diagnostics. By capturing the value chain of this disruptive theme, the portfolio provides a way to invest in the shift towards more personalized and effective medical treatments. The underlying companies are driving innovation that could lead to breakthroughs in combating genetic disorders, cancer, and other complex diseases, representing a significant long-term growth opportunity.

The investment strategy is built upon a globally diversified index of companies from both developed and emerging markets. This includes established pharmaceutical and biotechnology giants that are heavily investing in genomic R&D, as well as smaller, more specialized firms focused on cutting-edge technologies. This approach allows investors to gain comprehensive exposure to the entire ecosystem, from the initial discovery and research phases to the commercialization of new drugs and therapies. The fund focuses on companies that derive a significant portion of their revenues from these innovative activities, ensuring a pure-play investment in the genomic revolution.

This thematic investment is suitable for those with a long-term perspective and a higher tolerance for risk, given the inherent volatility of the biotechnology and technology sectors. The key drivers for this theme include powerful structural tailwinds such as aging populations, rising global healthcare spending, and continuous technological advancements that lower the cost of genetic analysis. By providing a liquid and diversified vehicle, the fund allows investors to participate in the potential upside of one of the most transformative trends in modern healthcare, aiming for long-term capital appreciation.